Stem Cells and Cell Therapies in Lung Biology and Lung Diseases

Supported by the National Heart, Lung, and Blood Institute, Alpha-1 Foundation, American Thoracic Society, LAM Treatment Alliance Pulmonary Fibrosis Foundation, University of Vermont College of Medicine, Vermont Lung Center

> Burlington, Vermont July 25-28, 2011

AGENDA

MONDAY, JULY 25

5:00-7:00 PM Welcoming Reception and Registration, Sheraton Hotel

TUESDAY, JULY 26

6:30-7:15 AM	Shuttle bus looping between Sheraton and UVM Campus			
6:45-7:15	Continental Breakfast and Continued Registration Grand Maple Ballroom, Davis Center, UVM Campus			
7:15-7:30	Welcome and Introduction			
Session 1:	Endogenous Lung Progenitor Cells/Lung Cancer Stem Cells Moderator: Jay Rajagopal, PhD			
7:30-8:15	Introductory Overview: Leonard Zon, MD	Critical Overview of Endogenous Progenitor Cells in the Lung		
8:15-9:00	Emma Rawlins, PhD	Endogenous Progenitor Cells: Lessons from Lung Development		
(All subsequent talks: 20 min followed by a 10 min Q/A period)				
9:00-9:30	Ivan Bertoncello, PhD	Characterization and Organization of Endogenous Stem Cells in the Adult Lung		
9:30-10:00	Carla Kim, PhD	Stem Cell Approaches to Understand Lung Injury Repa and Lung Cancers		
10:00-10:30	BREAK			

10:00-10:30	Susan Reynolds, PhD	Beta-Catenin Regulates Basal Cell – Cell Fate	
10:30-11:00	Barry Stripp, PhD	Is the Airway Epithelium Maintained by Multipotent or Region-Specific Progenitor Cells?	
11:00-11:30	Mark Magnuson, MD	The Beta Cell Biology Consortium: Ten Years of Team Science	
11:30-12:30 PM	Panel Moderated Discussion	Panelists Wellington Cardoso MD PhD, David Warburton PhD	
12:30-2:00	Lunch and Poster Session		
Session 2:	Embryonic Stem Cells, iPS, and Lung Regeneration Moderator: Carolyn Lutzko, PhD		
2:00-2:30	Featured Speaker: Jeffrey Whitsett, MD	Phenotypic and Functional Identification of Lung Epithelial Cells: Is That Really a Type 2 Cell?	
2:30-3:00	Featured Speaker: Gustavo Mostoslavsky, PhD	iPS Cells, The Good, Bad, and Ugly	
3:00-3:15	BREAK		
3:15-3:45	Ali Samadikuchaksaraei PhD	Embryonic Stem Cells Differentiation into Pulmonary epithelial Cells	
3:45-4:15	Darrell Kotton, MD	Derivation of Ttf1+Endodermal Progenitors from ES and iPS Cells	
4:15-4:45	Amy Wong, PhD	Establishment of CFTR-Expressing Epithelial Cells from Pluripotent Stem Cells	
4:45-5:15	Hans-Willem Snoeck, MD, PhD	Generation of Anterior Foregut Endoderm from Human Pluripotent Cells	
5:15-5:45	Brian Davis, PhD	Gene Corrected iPS-Derived Lung Cells for Therapy of Inherited Lung Diseases	
5:45-6:30	Panel Moderated Discussion	Panelists: Barbara Driscoll PhD, Jeff Spees PhD	
7:30	Dinner/Reception ECHO Scienc	e Center, Burlington	

WEDNESDAY, JULY 27

7:00 – 7:30 AM	Continental Breakfast			
Session 3:	Bioengineering Approaches to Structure and Matrix Moderator: Jason HT Bates, PhD	Lung Regeneration:		
7:30-8:00	Featured Speaker Dame Julia Polak, DBE, MD, DSc	Lung Tissue Engineering: Past, Present and Future Opportunities		
8:00-8:30	Featured Speaker: Paolo Macchiarini, MD	Cell Therapy and Bioengineered Replacement of the Airways		
8:30-9:00	Joaquin Cortiella, MD	The Role of Natural Matrix in the Development of Lung Tissue Using Embryonic, Mesenchymal, or Fetal Lung Cells		
9:00-9:30	Christine Finck, MD	Bioengineering of the Lung		
9:30-10:00	BREAK			
10:00-10:30	Andrew Hoffman, DVM, DVSc	Biological Scaffolds to Enhance Progenitor Cell Transplantation		
10:30-11:00	Peter Lelkes, PhD	De-Cellularization and Beyond		
11:00-11:30	Angela Panoskaltsis-Mortari, PhD	Using Decellularized Matrices for Bioengineering the Lung		
11:30-Noon	Laura Wangensteen MD PhD	Optimizing Lung De-Cellularization and Re-Cellularization with Stem Cells		
Noon-1:00	Lunch and Poster Session: University of Vermont			
Session 4:	Bioengineering Approaches to Lung Regeneration: Function Moderator: Thomas Gilbert, PhD			
1:00-1:30	Featured Speaker Doris Taylor, PhD	Developing Biologically Active Scaffolds for Regeneration or Repair		
1:30-2:00	David Hoganson, PhD	Lung Tissue Engineering Based on Engineered Vascular Scaffold		

2:00-2:30	D. Daniel Huh, PhD	A Human Breathing Lung-on-a-Chip		
2:30-3:00	Laura Niklason, PhD	Engineering Functional Lung Tissues		
3:00-3:30	BREAK			
3:30-4:00	Harald Ott, MD	Engineering and Transplantation of a Bioartificial Lung		
4:00-4:30	Daniel Tschumperlin, PhD	The Mechanical Microenvironment's Influence on Cell Signaling and Differentiation		
4:30-5:00	Jason Woods, PhD	Imaging in Lung Regenerative Medicine		
5:00-6:00	Panel Moderated Discussion	Panelists: Mingyao Liu PhD, Joan Nichols PhD		
6:00	Free evening in Burlington			
THURSDAY	7, JULY 28			
7:00-7:30 AM	Continental Breakfast			
Session 5:	EPCs, MSCs and Cell Therapy Approaches for Lung Diseases Moderator: Armand Keating, MD			
7:30-8:00	Featured Speaker: Darwin Prockop, MD, PhD	Potential Therapies with the Anti-inflammatory Protein TSG-6 and the Anti-ROS Protein STC-1 Produced by		
8:00-8:30	Featured Speaker: Jacques Galipeau, MD	Adult Stem/Progenitor Cells (MSCs) The Immune Plasticity of MSC: Impact on Design of Cell Therapy Studies.		
8:30-9:00	Sam Janes, PhD	Stem Cell Therapy for Lung Metastases		
9:00-9:30	Michael Matthay, MD	Mesenchymal Stem Cells for Acute Lung Injury		

9:30-10:00 BREAK

10:00-10:30

10:30-11:00

11:00-11:30

Duncan Stewart, MDAn Update on Cellular Therapies for Pulmonary
Vascular Diseases: Moving Towards an Efficacy TrialDaniel J. Weiss, MD, PhDMSC Immunomodulation of Airways Diseases

Mervin Yoder, MD Define Human Endothelial Progenitor Cells

11:30-12:00	Donald Phinney PhD	Functional H for Clinical T	leterogeneity of MSCs and Implications Therapies
12:00-12:30PM	Panel Discussion with Box Buffe	t Lunch	Panelist: Polly Parsons MD
Session 6:	<u>Summation and Directions</u> Moderator: Darwin Prockop, MD, PhD Texas A & M		
12:30-1:45 PM	Perspectives from the NIH, NASA, FDA, Respiratory Disease Foundations James Kiley PhD , Chief, Davison of Lung Diseases, NHLBI Christine Kelley PhD, NIBIB Neal Pellis PhD, NASA Donald Fink, Jr., PhD, FDA Adam Wanner, MD, Alpha-1 Foundation Michael Matthay, MD on behalf of the ATS Amy Farber MD, Director LAM Foundation Daniel Rose, PhD, CEO Pulmonary Fibrosis Foundation		
1:45-2:30	Open Discussion: Setting Priorit Regarding Future Research Opp		nmendations to the NIH
2:30	Conclusion		